Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Biomarker for Avastin
By gdpawel at 2011-11-25 10:07
For some time, clinicians have been grumbling about not having a biomarker for Avastinterm or any other anti-angiogenesis compound to better help choose which patients would be most likely to respond, thereby avoiding the need to treat everyone to gain a benefit in a few.

One of the biggest challenges with Vascular Endothelial Growth Factor (VEGFterm) therapy has been the lack of a predictive biomarker.

read more | 3 comments | 19999 reads

Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures of breast cancer and other human neoplasms
By gdpawel at 2008-09-12 04:09

Antivascular activity of lapatinib and bevacizumabtermterm in primary microcluster cultures of breast cancer and other human neoplasms

Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other

Category: Treatment

Meeting: 2008 Breast Cancer Symposium

Abstract No: 166

Author(s): L. Weisenthal, D. J. Lee, N. Patel



The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinibterm (Su), sorafenibterm (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).

read more | 1 comment | 4328 reads

Taxol with avastin produces noteworthy results
By Dross at 2007-12-27 23:47

NDIANAPOLIS – The positive results of the first nationwide clinical study showing the benefits of an antiangiogenic agent in breast cancer therapy are reported in the Dec. 27 issue of the New England Journal of Medicine.

The study with Avastinterm showed the biggest improvement in metastaticterm breast cancer ever reported in a chemotherapyterm-based clinical trial. It nearly doubled the time between initiation of chemotherapy for metastatic disease and progression of the breast cancer tumors.

The study was coordinated by the Eastern Cooperative Oncology Group (ECOG) and Kathy Miller, M.D., associate professor of medicine and Sheila D. Ward Scholar at the Indiana University School of Medicine, is the lead author.

read more | 4 comments | 3062 reads

Bevacizumab found to improve survival for patients with advanced breast cancer
By Dross at 2007-12-27 23:46

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastaticterm breast cancer according to results of a large clinical trial of Avastinterm, an anti-angiogenic therapy. The study, published in the December 27th issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapyterm significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.

Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

read more | 4 comments | 2211 reads

PF-3512676 (CPG 7909) Non-Small-Cell-Lung Immuno-modulatory Treatment Development History
By HCat at 2007-03-17 07:11

    Coley Phamaceutical Group has developed oligonucleotides which contain CpG motifs (the nucleotides cytosine and guanine in repetition) that help immune responses. The oligonucleotides illicit an immune response by affecting toll-like receptor (TLR) function, with the main one being TLR9. Here is a link to a basic picture of TLR function in the immune response from the company website. The CpG motifs in bacterial DNA have been shown years ago to illicit an immune response. Here is a link to an abstract of a paper on induction of an immune response by CpG motifs from bacterial DNA.

read more | 9043 reads

Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Survival
By Dross at 2007-02-23 05:23



Genentech, Inc. (NYSE:DNA) announced today that a Roche-sponsored Phase III study evaluating two different doses of Avastinterm(R) (bevacizumabtermterm) in combination with gemcitabine and cisplatin chemotherapyterm met the primary endpoint of prolonging progression-free survival (PFS) in patients with previously untreated, advanced non-squamous, non-small cell lung cancer (NSCLC), the most common form of the disease. Both doses of Avastin (15 mg/kg or 7.5 mg/kg every three weeks) significantly improved PFS compared to chemotherapy alone, as assessed by trial investigators. Although the study was not designed to compare the Avastin doses, a similar treatment effect in PFS was observed between the two arms. No new safety signals related to Avastin were observed in the study. More than 1,000 patients from outside of the United States participated in the trial, known as AVAiL (BO17704).

"In addition to supporting Avastin's benefit in advanced lung cancer, these results demonstrate Avastin's potential when used in combination with a different chemotherapy regimen," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "We will continue to analyze these data to better understand the benefit and relative safety of each arm and these findings will be presented at an upcoming medical meeting."

read more | 9 comments | 2188 reads

PER.C6 Technology from Crucell Could Soon Herald Lowered Costs for Antibody Treatments
By HCat at 2007-02-21 02:40

    Crucell in a partnership with DSM have announced that production of monoclonal antibodies has reached 10g/L (grams per liter) of cell culture, using the PER.C6 platform to produce the yields. Current standard methods yield monoclonal antibodies around 1-2g/L. This order of magnitude increase in yield could help lower the cost for producing the current monoclonal antibodies used in treatments for cancer today. The price of drugs has soared for cancer treatment and the monoclonal antibodyterm is no exception. Herceptin costs around $3,000 a month, Avastinterm is at $4,400, Erbituxterm costs around $10,000 a month, and Rituxanterm can range from $4,200 to $13,000 a month depending on treatment. A great article on recent drug costs can be found here on the USA Today site.


read more | 3653 reads

Cancer drug can extend survival in patients with deadly brain tumors
By Dross at 2007-02-20 23:56

DURHAM, N.C. -- Avastinterm, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found. The study marks the first time that Avastin has been tested against brain tumors, the researchers said. The drug, whose chemical name is bevacizumabtermterm, currently is used to treat lung and colorectal cancers. The researchers tested the effectiveness of Avastin in conjunction with a standard chemotherapyterm agent in patients with recurrent cancerous brain tumors called gliomas. They found that the two drugs together halted tumor growth up to twice as long as comparative therapies.

read more | 3328 reads

INGN 241 in Combination with Avastin Results in Complete Tumor Regression in Lung Cancer
By HCat at 2007-01-25 10:42

    AUSTIN, Texas--(BUSINESS WIRE)--Jan. 24, 2007--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today the publication of data in Molecular Therapy, the journal of the American Society of Gene Therapy, highlighting the results of a preclinical study with INGN 241 in combination with Avastinterm(R) (Bevacizumabtermterm). Synergistic activity resulting in a curative therapeutic effect was seen in the treatment of lung cancer following the combination of the two agents. In contrast, treatment with Avastin alone demonstrated only minor tumor regression and no animals were cured of their cancer. The study was conducted at The University of Texas M.D. Anderson Cancer Center by Introgen's collaborator Dr. Rajagopal Ramesh, associate professor, Department of Thoracic and Cardiovascular Surgery.

read more | 4767 reads

Colorectal Cancer Basics
By HCat at 2007-01-16 12:35

Colorectal Cancer Basics


Hereditary CRC

Colorectal cancer (CRC) can be divided into two basic types, hereditary or sporadic.

    Hereditary CRC are germlineterm (passed to offspring) mutations (a damaging change in DNA) with two well described forms. These hereditary mutations are thought to reduce the time it takes for the cells to turn cancerous. Mutations can be thought of in terms of “hits”. One hit is one mutation. It is thought that a normal cell needs 3 to 6 hits to become cancerous. With an inherited mutation, there is one fewer hit needed to reach the correct number to transform the cell to cancer. One odd aspect to CRC is that there is a relatively well defined set of events for the progression from adenomaterm to carcinomaterm.

read more | 29317 reads

New England Journal of Medicine Avastin in Lung Cancer
By admin at 2006-12-19 03:00

New England Journal of Medicine Publishes Data from Pivotal Study of Avastinterm Plus Chemotherapyterm in Most Common Type of Lung Cancer


 Genentech, Inc. (NYSE-DNA) announced today the publication of data from a pivotal Phase III clinical trial in the New England Journal of Medicine showing that Avastin(R) (bevacizumabtermterm) in combination with paclitaxel and carboplatin chemotherapy significantly improved overall survival in patients with unresectable, locally advanced, recurrent or metastaticterm non-squamous, non- small cell lung cancer (NSCLC), the most common type of lung cancer.

read more | 1 comment | 2887 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 12:22 PM.